GRI Bio Statistics
Total Valuation
GRI Bio has a market cap or net worth of $2.98 million. The enterprise value is -$8.01 million.
Important Dates
The last earnings date was Thursday, May 14, 2026, before market open.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GRI Bio has 1.45 million shares outstanding. The number of shares has increased by 3,546.32% in one year.
| Current Share Class | 1.45M |
| Shares Outstanding | 1.45M |
| Shares Change (YoY) | +3,546.32% |
| Shares Change (QoQ) | +518.40% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 2.00% |
| Float | 1.45M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.31 |
| P/TBV Ratio | 0.28 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.21, with a Debt / Equity ratio of 0.01.
| Current Ratio | 14.21 |
| Quick Ratio | 13.91 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -185.67% and return on invested capital (ROIC) is -114.65%.
| Return on Equity (ROE) | -185.67% |
| Return on Assets (ROA) | -88.82% |
| Return on Invested Capital (ROIC) | -114.65% |
| Return on Capital Employed (ROCE) | -103.64% |
| Weighted Average Cost of Capital (WACC) | 0.02% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.73M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -94.67% in the last 52 weeks. The beta is -0.77, so GRI Bio's price volatility has been lower than the market average.
| Beta (5Y) | -0.77 |
| 52-Week Price Change | -94.67% |
| 50-Day Moving Average | 2.36 |
| 200-Day Moving Average | 23.94 |
| Relative Strength Index (RSI) | 37.65 |
| Average Volume (20 Days) | 32,059 |
Short Selling Information
The latest short interest is 107,369, so 7.43% of the outstanding shares have been sold short.
| Short Interest | 107,369 |
| Short Previous Month | 134,378 |
| Short % of Shares Out | 7.43% |
| Short % of Float | 7.43% |
| Short Ratio (days to cover) | 0.70 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -10.93M |
| Pretax Income | -10.91M |
| Net Income | -10.91M |
| EBITDA | -10.93M |
| EBIT | -10.93M |
| Earnings Per Share (EPS) | -$27.02 |
Full Income StatementBalance Sheet
The company has $11.05 million in cash and $58,000 in debt, with a net cash position of $10.99 million or $7.61 per share.
| Cash & Cash Equivalents | 11.05M |
| Total Debt | 58,000 |
| Net Cash | 10.99M |
| Net Cash Per Share | $7.61 |
| Equity (Book Value) | 10.55M |
| Book Value Per Share | 6.65 |
| Working Capital | 10.49M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$12.14 million and capital expenditures -$3,000, giving a free cash flow of -$12.14 million.
| Operating Cash Flow | -12.14M |
| Capital Expenditures | -3,000 |
| Depreciation & Amortization | 4,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -12.14M |
| FCF Per Share | -$8.40 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GRI Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3,546.32% |
| Shareholder Yield | -3,546.32% |
| Earnings Yield | -366.44% |
| FCF Yield | -407.76% |
Analyst Forecast
The average price target for GRI Bio is $25.00, which is 1,113.59% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $25.00 |
| Price Target Difference | 1,113.59% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 26, 2026. It was a reverse split with a ratio of 1:28.
| Last Split Date | Jan 26, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:28 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
